HCV / Hepatitis

Brii Biosciences presented new data from Phase 2 trials for chronic hepatitis B at EASL Congress 2024, revealing insights into the efficacy of BRII-179 as botha combined therapy and an additional treatment.

Innovative approach across opioid treatment programs bridges geographical barriers, achieving cure rates, and unlocking health benefits for underserved populations.

Atea pharmaceuticals is presenting data at a European liver conference this week showing a high efficacy for its combination therapy at 12 weeks post-treatment.

The clearance rate varied across states, but were not close to the 2025 or 2030 goals across all jurisdictions.

FDA approves Moderna's RSV vaccine for seniors, young women struggling with recurrent C difficile over the years, FDA grants Karius test to assist diagnosing infectious diseases, and more this week from Contagion.

A newer strategic approach combined with existing treatments are together trying to reduce incidence rates and cure people of HCV, but barriers to treatment remain, and often leave people outside the continuum of care.

This report underscores the increase of STIs alongside the ongoing global epidemics of HIV and viral hepatitis in the Americas and African regions.

Public health officials have confirmed 5 cases since mid-March with a separate case associated with a grocery store employee.

This week, irrigation water in Utah creates E coli outbreak, FDA issues CRL for HEPLISAV-B 4 dose regimen, living with C diff awareness, and more this week from Contagion.

Hepatitis awareness remains essential to promote prevention and early detection, ensuring access to vaccination and treatment, and improving public health.

Research indicates serum LOXL2 levels could serve as a predictor for hepatocellular carcinoma (HCC) risk in HCV patients who have achieved sustained virological response (SVR).

Dynavax is currently reviewing FDA feedback and strategizing a meeting to discuss their HEPLISAV-B 4-dose regimen for hemodialysis patients, determining the path forward toward approval.

Study examines the scarcity of data on the incidence of HBV-related hepatocellular carcinoma in West Africa.

On the day of a FDA PDUFA for a hepatitis B vaccine, it serves as reminder of great progress, but there remains a need to proliferate education especially around the liver.

Analysis reveals rising hospitalization rates among pregnant women with hepatitis C virus (HCV) and age as a critical factor influencing maternal and fetal health outcomes.

The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.

This week, April FDA roundup, ESCMID conference coverage, enhancing C difficile treatment, and more from Contagion.

This study monitored viral load in asymptomatic blood donors, unveiling insights into the progression of HEV infections, vital for public health strategies.

Public health alert over ground beef, FDA approves antibiotics for female adults with uncomplicated UTI, The NYC Department of Health and Mental Hygiene reports a record amount of Leptospirosis cases, and more this week from Contagion.

Study from the Journal of Hepatology aims to characterize immune responses associated with rapid natural clearance of HCV reinfection.

The vaccine’s developer, YS Biopharma, will begin its phase 1 clinical trial in the Philippines this summer.

Study highlighting the first documented case of C auris moving from adult to pediatric unit in Maryland, COVID-19 physical health problems lingering 1 year after their hospital stay, 5-in-1 meningococcal vaccine given FDA PDUFA, and more this week from Contagion.

Please join advocates for prevention to celebrate the miracles the liver performs in maintaining the bodies’ systems, and ways to increase education to the public about the organ.

An analysis of NHANES data looked at HCV infection and risk of prostate cancer, and found contrary evidence from previous research.

Current progress of WHO's strategies to enhance global health outcomes through improved diagnosis and treatment of viral hepatitis.